T. Rowe Price holds 5.4% of ORIC (ORIC) — 5.39M shares reported

Rhea-AI Filing Summary

ORIC Pharmaceuticals reported that T. Rowe Price Associates, Inc. beneficially owned 5,387,783 shares of Common Stock, representing 5.4% of the class as of 03/31/2026. The filing lists sole voting power of 5,382,293 shares and sole dispositive power of 5,387,783. The filer includes a written statement denying beneficial ownership.

Insights

Institutional Ownership Analyst

Large passive position disclosed by T. Rowe Price at 5.4% of ORIC.

The filing shows 5,387,783 shares and a 5.4% stake as of 03/31/2026, with voting and dispositive powers reported in nearly identical amounts. This identifies a sizeable institutional position visible in public ownership records.

Holder intent, trading plans, and cash‑flow treatment are not stated in the excerpt; subsequent filings would show any changes in ownership or voting behavior.

Key Figures

Reporting date: 03/31/2026 Shares beneficially owned: 5,387,783 shares Percent of class: 5.4% +4 more

7 metrics

Reporting date 03/31/2026 date tied to reported ownership

Shares beneficially owned 5,387,783 shares Amount reported in Schedule 13G

Percent of class 5.4% Percent of common stock reported

Sole voting power 5,382,293 shares Number with sole power to vote reported

Sole dispositive power 5,387,783 shares Number with sole power to dispose reported

CUSIP 68622P109 Identifier for ORIC Common Stock

Signature date 05/15/2026 Date filing signed by filer representative

Key Terms

Schedule 13G, Beneficial ownership, Sole dispositive power, Sole voting power

4 terms

Schedule 13G regulatory

"T. Rowe Price Associates, Inc. 2 | 4 | Citizenship"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficial ownership regulatory

"Amount beneficially owned: 5387783 (b) | Percent of class: 5.4 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 5387783"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Sole voting power financial

"Sole power to vote or to direct the vote: 5382293"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ORIC PHARMACEUTICALS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

68622P109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 68622P109

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,382,293.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,387,783.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,387,783.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ORIC PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 68622P109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5387783
(b)	Percent of class: 5.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5382293
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5387783
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026

FAQ

What stake does T. Rowe Price report in ORIC (ORIC)?

T. Rowe Price reports beneficial ownership of 5,387,783 shares, representing 5.4% of ORIC's common stock as of 03/31/2026. The filing also lists sole voting power of 5,382,293 shares.

Does the Schedule 13G show whether T. Rowe Price controls voting of ORIC shares?

The filing shows sole voting power of 5,382,293 shares, indicating the filer reports voting authority for that number. The document does not state any planned votes or voting commitments.

When was the Schedule 13G signed for ORIC by T. Rowe Price?

The Schedule 13G is signed by Ellen York, Vice President, on 05/15/2026. The reported ownership figures are tied to the 03/31/2026 reporting date shown in the excerpt.

Does T. Rowe Price claim to be the beneficial owner of ORIC shares?

The filing includes a statement that the filing "shall not be construed as an admission" of beneficial ownership and that such beneficial ownership is "expressly denied." That disclaimer is part of the disclosed text.

What CUSIP and class are reported in the ORIC filing?

The filing identifies the security as Common Stock with CUSIP 68622P109. This is the class and identifier referenced in the ownership disclosure.